Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Interesting that Merck is partering with another biotech company for cancer, and is following the same path that they did with Ariad's Rida:
http://www.thestreet.com/story/11496446/1/endocyte-shares-rise-on-merck-cancer-deal.html?cm_ven=GOOGLEN
That's down $.82 in two days! (low volume, however)
We are now in no man's land..
Well, you have a huge double top staring you in the face..good luck!
Well, after snooping around, we finally know who sold their shares (hedge):
Ariad Pharma Sees Huge Setback In Its Sarcoma Maintenance Drug Ridaforolimus [View article]
My cost basis in ARIA was 2.4235 from 2008. My sales were recorded in 2011 at 13.35-13.49, and in 2012 at 14.60-15.55.
I think I have done more than OK in ARIA over the years, and have no current position. I will be more than happy to buy ARIA back either lower (on a macro pullback), or higher (on a momentum breakout). Right now, it is in no mans land, so I have no position, and waiting. '113 could add an additional $1 billion to the market cap once data becomes available.
It is absolutely laughable that you continue to say that you have consulted with KOLs in CML who have "concerns" about toxicity re: ponatinib. There is a lot of public data and commentary from these same KOLs - ponatinib has less toxicity issues than those of gleevec, sprycel, and tasigna. I truly believe you have no idea what you are talking about and are simply making stuff up in an effort to sound intelligent.
Honestly, the more I debate this with you, I think I might be arguing with a "parody" account - are we being punked, LOL?
Yes, you can have your opinion. But, when your opinion is based on false fabrications and you cannot support your evidence of toxicity from these so called experts in CML, your statements become outright misleading.
Cheers.
http://seekingalpha.com/author/missouri-heights-alpha-fund/comments
The U.S. economic recovery also stumbled in each of the last two summers, but
that was not the only catalyst for the U.S. stock market corrections in those
two years. The euro-zone debt crisis was as big a concern.
Unfortunately, the euro-zone debt crisis, which seemed to have been resolved a
few months ago by the bailout of Greece and massive infusions of extra liquidity
into eurozone financial systems, has returned. And this time the focus is on
Spain, a much larger and more difficult economy to bail out than Greece should
it come to that. It was reported Friday that Spain’s banks had to borrow $416.7
billion from the ECB liquidity fund in March compared to $223.8 billion in
February. Borrowing by all banks in the 17-nation euro-zone in March totaled $1.48 trillion, and Spain accounted for 28% of it.
European stock markets have been responding to the new debt crisis concerns (as well as their slowing economies) since early March, with markets in Germany, France and the United Kingdom already down an average of 8% since the end of
February.
I don't know about that.. Things on a service that I follow peaked my interest is that the RS Strong Weak is getting into Oversold Area which when it reverses should give a nice pop.
The AAII sentiment index of Bulls has been cut in half over the last 2 weeks. Remember these people are usually wrong. This is one of my most favorite indicators..
However, there are storm clouds ahead as we enter the summer months..
I see many stocks breaking down now, and would not add here.. We are going through a period that simply is not good for risk assets..
More interesting, we now have entered the dreaded double top chart pattern... This is bad..!!
ariafan, that's one man's opinion from the yahoo message board.. 'Nuf said...
And, in an effort to combine the recent threads here, Wong Fly..
We are now in no man's land...
"Are you suggesting we may be long gone before this becomes an issue ?"
Is the Pope Catholic? Without question.
"Payment issues for cancer drugs."- This will take a few years, if ever, for the system to adjust. This will not happen over night as it would be highly destructive to the R&D system..
WOW, with Ariad's AP26113 now entering the UBS financial model, the rest of the firms will naturally have to follow... Sweet!!
http://www.thestreet.com/story/11492727/1/analysts-actions-aria-ea-hgsi-bbby.html?puc=yahoo&cm_ven=YAHOO
WOW, with AP26113 now entering the UBS model, the rest of the firms will naturally have to follow... Sweet!!
From CNBC:
Also on the health care front, UBS initiated coverage of a handful of pharmaceuticals with a "buy" rating, including Ariad [ARIA 15.14 0.19 (+1.27%) ] and Biomarin [BMRN 32.28 0.15 (+0.47%) ].
I expected a bigger bounce today..
flyonthewall, as the name implies, is worth a flyonthewall..
It's the $60's chatter that is pure nonsense, in the short-medium term.
I'm stunned that they are already marketing Pona so aggressively.. Incredible... in the NEJM. I knew Harvey was good, but didn't realize he is THAT good..
ariadndndough, thanks.. I must have missed that article..
What brokerage account allows you to place a market order AH? All my brokerage accounts require limit orders only AH..
MolecularMD closes $6 million financing
Important to Ariad..
http://www.marketwatch.com/story/molecularmd-closes-6-million-series-b-financing-and-announces-ensuing-growth-initiatives-2012-04-02
Ponatinib's application with other cancers just grew.. wonder compound? I think so..
to other tyrosine kinase inhibitors in acute myeloid leukemia, medullary thyroid cancer, gastrointestinal stromal tumor (GIST) and rare forms of leukemia driven by these tyrosine kinases.
http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1679065&highlight=
You will now be able to own the brilliant research team as well!
http://www.fool.com/investing/general/2012/04/01/the-no-1-reason-to-invest-in-the-motley-fools-ipo-.aspx?source=ihpdspmra0000001&lidx=1
lol
I think that even at this very early stage, the word is leaking out that '113 WORKS IN ALK LUNG CANCER!!!
adreamer, funny, your post first said that you sold everything at $16.70, close to the high of the day, then I noticed that you came back 10 minutes later to add, " I bought them back.." Interesting..
The important news from Ariad to be presented at AACR is that ALL mutation inhibition continues very well... this should set up the results very well for ASCO, namely, Ponatinib data continues to improve over time..
Ariad's ACCR Abstracts now posted:
First one on Pona:
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=86650fd2-9bf9-4582-bbf5-0d0c334be4d1&cKey=a6b15caa-9370-4b9f-8ea7-2849b5a582cf&mKey=%7b2D8C569E-B72C-4E7D-AB3B-070BEC7EB280%7d
Ariad's AACR Abstracts NOW AVAILABLE
Check out ALXN, one drug on the market for a blood treatment, 10,000 total patients in the world with this condition, has $ 1 billion in annual sales, AND A $17 BILLION MARKET CAP, with a share price of $93. Interesting article in Barrons today, basically saying that with growth rate slowing, it maybe overvalued. But Goldman raises PT to $105
Check out ALXN, one drug on the market for a blood treatment, 10,000 total patients in the world with this condition, has $ 1 billion in annual sales, AND A $17 BILLION MARKET CAP, .
Rida certainly looks like it was a cap on the share price due to the unknown reaction of a Rida failure. Now that the cap has been lifted, can we now run up into the Pona results in June? Stay tuned........
qutrader, as the old saying goes, talk is cheap...